EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy

Bernadeta Drymel iD, Katarzyna Tomela iD, Łukasz Galus, Agnieszka Olejnik-Schmidt iD, Jacek Mackiewicz iD, Mariusz Kaczmarek, Andrzej Mackiewicz iD, Marcin Schmidt iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26168063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Bernadeta Drymel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Food Microbiology, Poznań University of Life Sciences, 60-627 Poznań, Poland. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Feces, Melanoma, Immune Checkpoint Inhibitors. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre, Poland, Department of Biotechnology and Food Microbiology, Poznań University of Life Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota is recognized as one of the extrinsic factors that modulate the clinical outcomes of immune checkpoint inhibitors (ICIs), such as inhibitors targeting programmed cell death protein 1 (PD-1), in cancer patients. However, the link between intestinal barrier, which mutually interacts with the gut microbiota, and therapeutic effects has not been extensively studied so far. Therefore, the primary goal of this study was to investigate the relationship between intestinal barrier functionality and clinical outcomes of anti-PD-1 therapy in patients with advanced melanoma. Fecal samples were collected from 64 patients before and during anti-PD-1 therapy. The levels of zonulin, calprotectin, and secretory immunoglobulin A (SIgA), which reflect intestinal permeability, inflammation, and immunity, respectively, were measured in fecal samples (n = 115) using an Enzyme-Linked Immunosorbent Assay (ELISA). Moreover, the composition of the immunoglobulin (Ig)-bound (n = 108) and total stool microbiota (n = 117) was determined by the V3–V4 region of 16S rRNA gene sequencing. ELISA indicated a higher baseline concentration of fecal SIgA in patients with favorable clinical outcomes than those with unfavorable ones. Moreover, high baseline concentrations of intestinal barrier state biomarkers correlated with survival outcomes. In the cases of fecal zonulin and fecal SIgA, there was a positive correlation, while in the case of fecal calprotectin, there was a negative correlation. Furthermore, there were differences in the microbial profiles of the Ig-bound stool microbiota between patients with favorable and unfavorable clinical outcomes and their changes during treatment. Collectively, these findings indicate an association between intestinal barrier functionality and clinical outcomes of anti-PD-1 therapy in advanced melanoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeFecesMelanomaImmune Checkpoint InhibitorsIntestinal MucosaProgrammed Cell Death 1 ReceptorHumansMaleFemaleMiddle AgedAgedAdultHaptoglobinsImmunoglobulin A, SecretoryRNA, Ribosomal, 16SProtein Precursors

Stichwörter der Autor:innen

advanced melanomagut microbiotaimmune checkpoint inhibitorsintestinal barriersecretory immunoglobulin A

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHaptoglobinszonulinImmunoglobulin A, SecretoryRNA, Ribosomal, 16SProtein Precursors

Autor:innen und Institutionen

  • Department of Biotechnology and Food Microbiology, Poznań University of Life Sciences, 60-627 Poznań, Poland.
  • Department of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
  • Department of Medical and Experimental Oncology, Institute of Oncology, Poznań University of Medical Sciences, 60-355 Poznań, Poland.
  • Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Centre, 61-866 Poznań, Poland.

ORCID-Profile: Bernadeta Drymel, Katarzyna Tomela, Agnieszka Olejnik-Schmidt, Jacek Mackiewicz, Andrzej Mackiewicz, Marcin Schmidt

Förderung

  • National Science Center
  • National Science Centre, Poland
  • Department of Biotechnology and Food Microbiology, Poznań University of Life Sciences

Zitieren

APA

Drymel, B., Tomela, K., Galus, Ł., Olejnik-Schmidt, A., Mackiewicz, J., Kaczmarek, M., Mackiewicz, A., & Schmidt, M. (2025). Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26168063

Vancouver

Drymel B, Tomela K, Galus Ł, Olejnik-Schmidt A, Mackiewicz J, Kaczmarek M, et al. Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26168063

BibTeX
@article{Drymel2025,
  author = {Drymel, Bernadeta and Tomela, Katarzyna and Galus, Łukasz and Olejnik-Schmidt, Agnieszka and Mackiewicz, Jacek and Kaczmarek, Mariusz and Mackiewicz, Andrzej and Schmidt, Marcin},
  title = {Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26168063}
}
Kostenlos starten →